Why is Biogen, Inc. ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.99 times
2
Positive results in Mar 26
- OPERATING CASH FLOW(Y) Highest at USD 2,590.8 MM
- DEBT-EQUITY RATIO (HY) Lowest at 12.22 %
- RAW MATERIAL COST(Y) Fallen by 1.92% (YoY)
3
With ROE of 10.01%, it has a fair valuation with a 1.72 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 58.06%, its profits have risen by 8.4% ; the PEG ratio of the company is 2.3
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 3.58% over the previous quarter.
5
Market Beating Performance
- The stock has generated a return of 58.06% in the last 1 year, much higher than market (S&P 500) returns of 22.24%
How much should you hold?
- Overall Portfolio exposure to Biogen, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Biogen, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Biogen, Inc.
58.06%
-0.38
33.68%
S&P 500
22.24%
1.67
13.28%
Quality key factors
Factor
Value
Sales Growth (5y)
-2.11%
EBIT Growth (5y)
3.08%
EBIT to Interest (avg)
8.05
Debt to EBITDA (avg)
1.60
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.41
Tax Ratio
15.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.77%
ROE (avg)
19.32%
Valuation Key Factors 
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.72
EV to EBIT
14.01
EV to EBITDA
10.59
EV to Capital Employed
1.63
EV to Sales
3.56
PEG Ratio
2.25
Dividend Yield
NA
ROCE (Latest)
11.63%
ROE (Latest)
10.01%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Movement
7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 2,590.8 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 12.22 %
RAW MATERIAL COST(Y)
Fallen by 1.92% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 5.07 times
-2What is not working for the Company
ROCE(HY)
Lowest at 7.7%
Here's what is working for Biogen, Inc.
Operating Cash Flow
Highest at USD 2,590.8 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at 12.22 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 5.07 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 1.92% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 204.4 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)






